small molecule

ELLA

ULIPRISTAL ACETATE

Loss of exclusivityJune 2030latest FDA-listed patent expiry
CompanyLABORATOIRE HRA PHARMA

Drug detail

Brand nameELLA
Active ingredientULIPRISTAL ACETATE
Strength30MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalAugust 2010
Marketing statusRX

Listed patents

PatentExpiresType
8426392June 2030use U-1389
8962603June 2030use U-1657
8512745June 2030product
10159681April 2030use U-2510
10772897April 2030use U-2958
9283233April 2030use U-1821
8735380February 2029product
9844510December 2028product

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

ELLA patent cliff — loss of exclusivity June 2030 | CliffBio